Chromosome 10 Deletion: Symptoms, Causes, and Diagnosis

Chromosome 10 deletions are rare chromosomal abnormalities in which a segment of genetic material is missing from one copy of chromosome 10. Because chromosome 10 carries hundreds of genes involved in brain development, heart formation, kidney function, and more, losing even a small piece can produce a wide range of symptoms depending on which region is affected. The clinical picture varies enormously, from a recognizable multi-organ syndrome in some individuals to subtle developmental delays in others, and understanding the location and size of the missing segment is the key to predicting what a person may experience.

Where the Deletion Occurs Matters More Than Its Name

Chromosome 10 has a short arm (called 10p) and a long arm (called 10q), separated by a central region. A deletion can happen on either arm, and the consequences differ dramatically depending on which genes are lost. Even within a single arm, two people with deletions of slightly different sizes can look clinically very different from each other, because one person’s deletion may remove a critical gene that the other person’s deletion spares.

Deletions are also classified by where on the arm the break occurs. A terminal deletion removes material from the breakpoint all the way to the tip of the chromosome arm. An interstitial deletion removes a segment from the middle, leaving the tip intact. Terminal deletions tend to be larger and affect more genes, but interstitial deletions can still be clinically significant if they happen to include a gene that plays an outsized role in development.

Short-Arm Deletions and Their Hallmark Syndromes

Deletions on the short arm of chromosome 10 (10p) are associated with two well-described clinical pictures, depending on which band of the chromosome is involved.

The better known of the two is Barakat syndrome, also called HDR syndrome, named for its three hallmark features: hypoparathyroidism, deafness, and renal disease. Fewer than 200 patients have been reported in the medical literature since the condition was first described in 1977. It is caused by loss or mutation of the GATA3 gene, located at band 10p14. GATA3 encodes a protein critical for the embryonic development of the parathyroid glands, the inner ear, and the kidneys, which explains why those three organs bear the brunt of the damage.¹ Not every person with a GATA3 deletion develops all three features, and the severity of each can range from mild hearing loss and borderline calcium levels to profound deafness and kidney failure.

Larger deletions that extend into the neighboring 10p13 band can produce a condition sometimes called DiGeorge syndrome type 2 (DGS2). This resembles the more common DiGeorge syndrome caused by a deletion on chromosome 22, but with its own profile. A review of patients with heart defects and 10p deletions found that atrial septal defect is a particularly common cardiac anomaly in DGS2, alongside kidney malformations and immune deficiencies related to thymic underdevelopment.² Children with DGS2 may struggle with recurrent infections because the thymus, which trains immune cells, did not form properly.

Long-Arm Deletions and 10q26 Deletion Syndrome

Deletions affecting the distal long arm of chromosome 10, particularly the region known as 10q26, produce a recognizable pattern often referred to as 10q26 deletion syndrome. The core features include facial differences, growth problems after birth, developmental delay, congenital heart defects, genital and urinary tract anomalies, finger or toe abnormalities, and eye-alignment issues such as strabismus.³ Congenital heart disease, craniofacial differences, and intellectual disability tend to appear consistently across reported cases.⁴

One feature that has drawn particular attention is asymmetric crying facies, a condition in which the lower lip droops on one side when a baby cries but appears normal at rest. A case report of a preterm infant with a 10q26.12-to-tip deletion documented this unusual facial feature alongside developmental delay, congenital heart disease, and pulmonary artery hypertension.⁵ The same report linked the loss of two specific genes in the 10q26.12-to-10q26.2 region, WDR11 and FGFR2, to the craniofacial differences, growth delay, intellectual disability, and cardiac problems seen in these patients.

Comparison studies looking at dozens of patients with 10q26 deletions of varying sizes suggest that a breakpoint around the 130-megabase position on the chromosome tends to produce the cluster of features most clinicians associate with the syndrome.⁶ Smaller or more distal deletions may produce a milder picture, particularly if they spare certain key genes.

Which Genes Drive the Cognitive Effects

One of the more active areas of research around 10q26 deletions involves figuring out which specific genes account for the intellectual disability and learning difficulties seen in so many affected individuals. Researchers have been steadily narrowing down the “critical region” by comparing patients with overlapping but slightly different deletions.

The strongest candidate gene is DOCK1, which encodes a protein involved in cell signaling and migration during brain development. A study identifying the smallest 10q26.2 deletion reported to date refined the minimal critical region and highlighted DOCK1 as the major driver, while also implicating two additional genes, INSYN2 and NPS, in cognitive function.⁷ A separate study further refined that interval to roughly 500 kilobases, centering on DOCK1 and INSYN2A as the genes most likely responsible for the cognitive phenotype of 10q26 microdeletion syndrome.⁸

This kind of gene mapping matters for more than academic curiosity. When clinicians find a small deletion in a prenatal or newborn test, knowing whether it includes DOCK1 or the surrounding critical region helps them counsel families about the likelihood and severity of cognitive effects. A deletion that falls outside this window may still cause some physical features but spare intellectual development, an important distinction for prognosis.

How Chromosome 10 Deletions Happen

Most chromosome 10 deletions arise de novo, meaning neither parent carries the deletion. They occur as random errors during the formation of eggs or sperm, or very early in embryonic cell division. There is no known environmental trigger, and parents who have a child with a de novo deletion have a low chance of having another affected child, though the risk is not quite zero because of the possibility of gonadal mosaicism, where a small fraction of a parent’s egg or sperm cells carry the deletion even though the parent’s blood test looks normal.

In a minority of cases, a deletion can result from an unbalanced translocation inherited from a parent who carries a balanced rearrangement. In a balanced translocation, pieces of two chromosomes have swapped places but no genetic material is missing, so the parent is typically healthy. When that parent’s cells divide to make eggs or sperm, however, the rearrangement can lead to offspring who receive extra material from one chromosome and missing material from another. One documented family illustrates this: two children with severe neurodevelopmental delay, speech problems, autistic features, and epilepsy were found to carry different unbalanced translocations between chromosomes 10 and 22, both inherited from a mother who carried a balanced translocation between those same chromosomes.⁹ Cases like these underscore why genetic testing of the parents is recommended after a child is diagnosed, because finding a balanced translocation in a parent changes the recurrence risk for future pregnancies substantially.

Why Symptoms Vary So Much Between Individuals

Even when two people share a deletion of nearly the same size and location, their symptoms can differ. Several factors account for this variability.

The most straightforward explanation is deletion size. A person missing 5 megabases of DNA has lost more genes than someone missing 1 megabase, and the extra missing genes can produce additional problems. But size alone does not tell the whole story. Some genes are more dosage-sensitive than others, meaning the body cannot tolerate having only one working copy. If a deletion happens to include one of these genes, even a tiny deletion can cause significant symptoms.

Another factor is mosaicism. Some individuals carry the deletion in only a fraction of their cells, with other cells having the normal chromosome complement. When this happens, the severity of symptoms often falls somewhere between a full deletion and no deletion at all. Research on mosaic genetic disease more broadly has shown that mosaicism can reduce the phenotypic severity of conditions that would otherwise be much more severe, and in some cases can even allow survival from deletions that would be lethal if present in every cell.¹⁰ The practical difficulty is that mosaicism detected in blood may not reflect mosaicism in brain or heart tissue, so clinical predictions remain imprecise.

The remaining copy of chromosome 10 also matters. If the non-deleted chromosome happens to carry a variant in one of the genes that the deleted region normally covers, the person effectively has no working copies of that gene instead of one. This “unmasking” of a recessive variant by a deletion has been documented in 10q26 cases, where a deletion on one chromosome revealed a disease-causing variant on the other, producing a condition that neither the deletion nor the variant alone would have caused.⁸

How Chromosome 10 Deletions Are Diagnosed

Diagnosis typically begins with clinical suspicion. A newborn with a combination of unusual facial features, a heart defect, and low muscle tone may prompt a geneticist to order chromosomal testing. In some cases, prenatal ultrasound abnormalities such as a heart malformation or growth restriction lead to testing before birth.

The traditional first-line test is a karyotype, which produces a visual image of all 46 chromosomes and can identify large deletions, typically those bigger than about 5 to 10 megabases. Karyotyping reliably picks up the larger terminal deletions seen in many 10p and 10q syndromes. However, it misses smaller deletions entirely, which is where chromosomal microarray analysis (CMA) becomes essential.

CMA scans the entire genome at a much higher resolution, detecting deletions and duplications as small as tens of kilobases. A large prenatal study found that CMA detected clinically significant genetic changes in about 0.67% of cases that karyotyping missed, and improved overall detection of genetic changes by roughly 4% compared to karyotyping alone.¹¹ That extra yield matters: a small interstitial 10q26 deletion that a karyotype would label as normal can be clearly identified on CMA, sometimes changing the clinical picture and management plan entirely.

One tradeoff of CMA’s higher resolution is the detection of variants of uncertain significance, or findings where it is not yet clear whether the deleted or duplicated region actually causes problems. In the same study, about 3.4% of the additional findings from CMA fell into this uncertain category.¹¹ For families undergoing prenatal testing, an uncertain result can be anxiety-provoking, and genetic counseling is important to put these findings in context. In postnatal settings, pairing the microarray result with the child’s actual clinical features usually resolves the ambiguity over time.

For cases where a deletion is found in a child, parental testing follows. Both parents typically have their chromosomes analyzed to determine whether the deletion arose de novo or was inherited from a parent carrying a balanced rearrangement. If a balanced translocation or other structural rearrangement is found in a parent, the family can be counseled about recurrence risks and offered options such as preimplantation genetic testing in future pregnancies.

PTEN and Chromosome 10 in Cancer

Not all chromosome 10 deletions are inherited or present from birth. Somatic deletions, meaning those acquired by individual cells during a person’s lifetime, can drive cancer. The most prominent example involves the gene PTEN, located at 10q23. PTEN acts as a tumor suppressor, and its loss is one of the most common genetic events across many cancer types.

In glioblastoma, the most aggressive primary brain tumor, PTEN deletion or mutation plays a central role in suppressing the immune response within the tumor environment. Growing evidence indicates that restoring PTEN function or targeting pathways downstream of it can improve the effectiveness of immunotherapy, making PTEN a focus of ongoing treatment research.¹² PTEN loss is also frequently seen in prostate cancer, endometrial cancer, and melanoma, among others.

It is worth emphasizing that somatic PTEN deletions in tumors are biologically distinct from the constitutional (present-from-birth) chromosome 10 deletions discussed earlier in this article. A child born with a 10q26 deletion does not have the same kind of PTEN loss seen in cancer, because the two regions of chromosome 10 are far apart. However, the fact that chromosome 10 houses both PTEN and the developmental genes disrupted in 10q26 syndrome illustrates how densely packed with important genes this chromosome is.

Living With a Chromosome 10 Deletion

Because chromosome 10 deletions affect multiple organ systems, management is almost always coordinated across specialties. A child diagnosed with 10q26 deletion syndrome, for instance, may see a cardiologist for a heart defect, an endocrinologist for growth monitoring, an ophthalmologist for strabismus or cataracts, and a developmental pediatrician for early intervention services. Children with 10p deletions involving GATA3 need regular monitoring of calcium levels and kidney function given the risk of hypoparathyroidism and renal disease.¹

Early intervention for speech and motor development is standard for children who show developmental delay. The degree of intellectual disability varies widely: some individuals with smaller deletions attend mainstream school with support, while others with larger deletions require more intensive services throughout their lives. Cardiac defects, when present, are often surgically repairable, and outcomes have improved considerably as pediatric cardiac surgery has advanced.

For families, the experience of receiving a chromosome 10 deletion diagnosis can be isolating, particularly because these conditions are rare enough that most pediatricians will not have seen a case before. Online registries and support groups organized around specific deletion syndromes have become valuable resources, connecting families who share similar diagnoses and helping them navigate the medical system. Genetic counselors serve a particularly important role, not only in explaining the test results and recurrence risks but also in helping families understand the wide range of possible outcomes, since the published case reports tend to skew toward more severe presentations and may not represent the full spectrum.

Prenatal Detection and the Limits of Prediction

Advances in prenatal testing mean that chromosome 10 deletions are increasingly discovered before birth, sometimes through CMA performed after an ultrasound flags a structural anomaly, and sometimes incidentally when noninvasive prenatal screening suggests an abnormality and follow-up diagnostic testing reveals a deletion. This earlier detection is a double-edged sword. On one hand, it allows families to prepare, connect with specialists, and plan delivery at a facility equipped to manage the child’s needs. On the other hand, predicting the severity of a deletion’s effects before birth remains genuinely difficult.

A fetus with a large terminal 10q deletion and a visible heart defect on ultrasound is likely to have a significant clinical course, but a fetus with a small interstitial deletion and no ultrasound findings is much harder to counsel about. The published literature on chromosome 10 deletions is inevitably biased toward more severely affected individuals, because those are the cases that get tested, diagnosed, and written up. Milder cases may go unrecognized for years or never be diagnosed at all, which means the medical literature probably overstates the average severity. Families facing a prenatal diagnosis should be aware of this reporting bias and seek counseling from a geneticist with experience in chromosomal disorders, rather than relying solely on what case reports suggest.